UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
|
|||
FORM 8-K
|
|||
CURRENT REPORT
|
|||
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
|||
Date of Report (Date of earliest event reported) May 29, 2014 |
RETROPHIN, INC.
|
|||
(Exact name of registrant as specified in its charter)
|
Delaware
|
000-53293
|
26-2383102
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
777 Third Avenue, 22nd Floor, New York, NY
|
10017
|
||
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code (646) 837-5863
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|||
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
||
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
||
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
||
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
(a)
|
The financial statements required to be filed by Item 9.01(a) of Form 8-K are not included in this report and will be filed by amendment to this Form 8-K no later than August 13, 2014.
|
|
(b)
|
The pro forma financial information required to be filed by Item 9.01(b) of Form 8-K is not included in this report and will be filed by amendment to this Form 8-K no later than August 13, 2014.
|
10.1
|
License Agreement, dated May 29, 2014, by and among Retrophin, Inc. and Mission Pharmacal Company. (Portions of Sections 2.3, 6.0, 7.0, 7.1, 8.0, 9.8, 10.0, 11.2, 17.0, 21.1, 21.2, 21.4, 22.0, 26.0, Exhibit A and Exhibit B of the Exhibit have been omitted pursuant to a request for confidential treatment and filed separately with the Commission.)
|
RETROPHIN, INC.
|
|||
Date: June 3, 2014
|
By:
|
/s/ Marc Panoff | |
Name: Marc Panoff
|
|||
Title: Chief Financial Officer
|
|||